Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
  • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
  • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
  • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
  • A61K31/425—Thiazoles
  • A61K31/429—Thiazoles condensed with heterocyclic ring systems
  • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
  • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
  • A61K9/1682—Processes
  • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/04—Antibacterial agents

Definitions

• This invention relates to agglomerates of ⁇ -lactam antibiotics, including e.g. penicillin V potassium, amoxicillin trihydrate, cephalexin monohydrate, which are suitable for direct tablet formation.
• ⁇ -lactam antibiotics including e.g. penicillin V potassium, amoxicillin trihydrate, cephalexin monohydrate, which are suitable for direct tablet formation.
• the most important and most frequently used form for orally administrable ⁇ -lactam antibiotics and mixtures, containing ⁇ -lactam antibiotics beside a second pharmaceutically active agent and optionally beside auxiliaries, is a tablet or a film tablet.
• a tablet or a film tablet there are at the moment two processes known, namely granulation and direct tablet formation.
• granulation generally very fine-grained, powdered, cohesive, non free-flowing and non-compressible pharmaceutically active agents are granulated in a multi-stage process to form coarser, free-flowing and compressible granules.
• the pharmaceutically active agents are mixed in a first step with a binding agent, compacted whilst moist or dry and subsequently granulated in a second step through a sieve.
• the binding agent may, e.g. be dissolved in the moistening liquid used for moistening and granulating the powder.
• drying of the granules is carried out including subsequent sieving to the final grain size.
• the granulates obtained may be mixed with auxiliaries which are preferably pharmaceutically acceptable required for tablet formation and compressed into tablets.
• Granulation is generally very time and energy consuming and expensive, and may be thus extremely uneconomical.
• the described production processes for a tablet requires a considerable amount of apparatus and a high amount of validation work, and owing to the large number of production steps there are many sources of error.
• Direct tablet formation is a much easier process; the pharmaceutically active agents being easily mixed with auxiliaries (carriers, binding agents, lubricants etc.) and the mixture is pressed into tablets.
• auxiliaries carriers, binding agents, lubricants etc.
• direct tablet formation could only be used to a limited extent, since it may generally only be carried out with, e.g. the following provisos:
• the pharmaceutically active agents has to be sufficiently free-flowing and compressible per se, and the proportion of pharmaceutically active agents per tablet must be a maximum of 100 mg or 25%. With such provisos good free-flow capability and good compressibility may only be obtained by addition of high amounts of special auxiliaries (e.g. Tablettose®, Ludipress® etc.).
• the proportion of the ⁇ -lactam antibiotic per tablet may be up to 80% and more (e.g. 1 g and more), and ⁇ -lactam antibiotics are generally not sufficiently free-flowing and compressible per se.
• penicillin V potassium, phenoxymethylpenicillin potassium, amoxicillin trihydrate and cephalexin monohydrate are generally obtained during production in an average volume-based grain size of 10 ⁇ m to 30 ⁇ m with the following grain size distribution:
• ⁇ -lactam antibiotics for example a combination of amoxycillin trihydrate ( ⁇ -lactam antibiotic) as, e.g. an anti-bacterially active compound with a second pharmaceutically active agent, e.g. a potassium salt of clavulanic acid (potassium clavulanate) as, e.g. a ⁇ -lactamase inhibitor are of enormous interest for the treatment of infections caused by gram-positive and gram-negative bacteria, which have become resistant to amoxycillin as a result of ⁇ -lactamase formation.
• a combination of amoxicillin trihydrate/potassium clavulanate/auxiliaries are on the market under the trade name Augmentin®.
• a potassium clavulanate may be extremely moisture sensitive and may degrade quickly in the presence of water
• a mixture of two pharmaceutically active agents in a defined ratio has to be produced which may include the danger of disintegration of the two components during production because, e.g. of inhomogeneous contents of a pharmaceutically active agent in a tablet or a film tablet
• the total proportion of the two pharmaceutically active agents per tablet may be up to 80% and more and the ability of the active ingredients to be compressed into a tablet or a film tablet may be determined almost exclusively by the physical properties of the active ingredients, i.e. deformation behaviour under pressure.
• the active ingredients amoxycillin trihydrate and potassium clavulanate are mixed in a first step with a binding agent, the mixture is moistened with a water-free, organic solvent, granulated and dried.
• the binding agent may also be added dissolved in the solvent.
• the granulates obtained may be sieved to the final grain size and mixed with tablet forming auxiliaries (binding agents, disintegrants etc.) before being compressed into tablets.
• auxiliaries binding agents, disintegrants etc.
• the active ingredients amoxycillin trihydrate and potassium clavulanate may generally be mixed with a binding agent and compacted in dry form. Compactation may take place by compressing the pharmaceutically active agent/binding agent-mixture either on a roller compactor to form so-called “shells” or on a tablet press having large stamps to form so-called “briquettes”. Both the shells and the briquettes obtained are pulverized or broken in a mill or a sieve, in order to obtain an appropriate granulate. After granulation it is generally necessary to separate the particles which are too coarse or too fine, and to recycle these particles, the coarse grain particles being pulverized again and the fine particles being compacted again (briquette formation).
• the granulates thus obtained may be mixed with auxiliaries required for tablet formation (lubricants, disintegrants etc.) which are preferably pharmaceutically acceptable and the mixture may be compressed to form tablets. Parts of the lubricants or disintegrants may be incorporated (mixed with active ingredient) prior to compacting/briquette formation.
• auxiliaries required for tablet formation lubricants, disintegrants etc.
• the mixture may be compressed to form tablets.
• Parts of the lubricants or disintegrants may be incorporated (mixed with active ingredient) prior to compacting/briquette formation.
• agglomerates of ⁇ -lactams including penicillin V potassium, amoxicillin trihydrate, cephalexin monohydrate which are free from auxiliaries and which have an excellent flowability, and which may be compressed directly into tablets optionally after mixing these agglomerates with auxiliaries; and a process for the production of free-flowing and auxiliary-free compressible ⁇ -lactam antibiotic agglomerates from powders.
• a mixture of pharmaceutically active agents including at least one ⁇ -lactam antibiotic such as a mixture of amoxycillin trihydrate and potassium clavulanate, containing optionally auxiliaries, suitable for the production of a tablet (or a film tablet) by direct tablet formation; and a process for direct tablet formation of a mixture of pharmaceutically active agents including at least one ⁇ -lactam antibiotic, such as a mixture of amoxycillin trihydrate and potassium clavulanate, containing optionally auxiliaries which are pharmaceutically acceptable, avoiding moisturing of the mixture in fewer production steps than according to prior art processes.
• ⁇ -lactam antibiotic such as a mixture of amoxycillin trihydrate and potassium clavulanate
• optionally auxiliaries which are pharmaceutically acceptable, avoiding moisturing of the mixture in fewer production steps than according to prior art processes.
• Auxiliary-free agglomerates of a ⁇ -lactam antibiotic are new and forms part of the present invention.
• auxiliary-free agglomerates of a ⁇ -lactam antibiotic which have an excellent flowability, and which may be compressed directly into tablets optionally after mixing with auxiliaries may be e.g. such, of an average volume-based grain size of 200 ⁇ m to 1000 ⁇ m, preferably 400 ⁇ m to 600 ⁇ m.
• the distribution of grain size may be as follows:
• ⁇ 100 ⁇ m 1% to 30%, for example 5% to 20% 100-500 ⁇ m: 10% to 80%, for example 20% to 60% 500-1000 ⁇ m: 10% to 80%, for example 25% to 60% >1000 ⁇ m: max. 30%, for example max. 15% >2000 ⁇ m: max. 0.5%, for example max. 0.1%.
• the bulk density of the agglomerates may, for example, be in the range of about 0.4 g/ml to about 0.8 g/ml, e.g. 0.4 g/ml to 0.8 g/ml; such as about 0.5 g/ml to about 0.7 g/ml, e.g. 0.5 g/ml to 0.7 g/ml.
• auxiliary-free agglomerates of ⁇ -lactam antibiotics especially of penicillin V potassium, amoxicillin trihydrate and cephalexin monohydrate; having for example an average volume-based grain size of 100 ⁇ m to 1000 ⁇ m, preferably 400 ⁇ m to 600 ⁇ m, such as 200 m to 600 ⁇ m; having for example the following distribution of grain size:
• ⁇ 100 ⁇ m 1% to 30%, for example 5% to 20% 100 ⁇ m to 500 ⁇ m: 10% to 80%, for example 20% to 60% 500 ⁇ m to 1000 ⁇ m: 10% to 80%, for example 25% to 60% >1000 ⁇ m: max. 30%, for example max. 15% >2000 ⁇ m: max. 0.5%, for example max. 0.1%;
• Auxiliary-free agglomerates according to the invention may be produced as follows:
• a solid ⁇ -lactam antibiotic e.g. penicillin V potassium, amoxicillin trihydrate and cephalexin monohydrate, e.g. in form of a powder, with an average volume-based grain size of 10 ⁇ m to 30 ⁇ m, with about the following distribution of grain size:
• a bulk density of 0.15 g/ml to 0.45 g/ml may be formed into a paste, for example by conventional methods, with a liquid in which the ⁇ -lactam antibiotic is insoluble or slightly soluble.
• This paste may be kneaded and extruded in a double-screwed extruder having a specific mechanical energy input of 0.01 to 0.1 kilowatt-hour/kg, preferably of 0.02 to 0.6 kilowatt-hour/kg.
• the temperature of the paste may be maintained in a range of about 10° C. to about 80° C., e.g. 10° C. to 80° C.
• Auxiliary-free agglomerates may be obtained which may be dried, e.g. as conventional, for example in a fluidized bed drier.
• the present invention provides a process for the production of auxiliary-free agglomerates of a ⁇ -lactam antibiotic, by the following steps
• the ⁇ -lactam e.g. in form of a powder
• the ⁇ -lactam antibiotic for example in form of a powder
• the liquid may be dispersed into the extruder simultaneously with the ⁇ -lactam antibiotic.
• Appropriate liquids include e.g. water, alcohols and mixtures thereof; as well as organic solvents such as acetone.
• An alcohol may preferably be ethanol or isopropanol.
• the amount of liquids may be appropriate to result in a kneadable paste with the ⁇ -lactam antibiotic and may be preferably as follows (expressed in % by weight, based on the paste):
• the optimum degree of density of the ⁇ -lactam antibiotic agglomerates may be such that mechanical stability of the agglomerates is appropriate, i.e. after drying, the agglomerates should not disintegrate into a powder because this would negatively affect the free-flow capability. But the agglomerates should not be extremely mechanical stable (density too high), because during the tablet formation process such extreme stable agglomerates would not be prone to form mechanically stable tablets which thus could not be produced.
• the optimum degree of density in a process according to the present invention corresponds exactly to the observed maximum torque pick-up on the extrusion screw which passes through during extrusion as the amount of liquid increases.
• the optimum degree of density of the powder is very easily controllable.
• the ⁇ -lactam agglomerates according to the present invention may be compressed, optionally after mixing with auxiliaries which are preferably pharmaceutically acceptable, such as polyvinyl pyrrolidone, talcum, magnesium stearate; directly into tablets of high unit weight, satisfactory mechanical stability and rapid release of of the ⁇ -lactam antibiotic (active ingredient). Since no binding agent and no bindings between the particles of active ingredient and a binding agent are generally present in the agglomerates as are generally present in moist granulation processes, the release of active ingredient from the directly compressed tablets according to the present invention may be considerably faster than from tablets produced by granulation as usual.
• auxiliaries which are preferably pharmaceutically acceptable, such as polyvinyl pyrrolidone, talcum, magnesium stearate
• the tablets produced according to the present invention by direct tablet formation of the new-type agglomerates of active ingredient have, e.g. the following advantages:
• the weight deviation of the tablets is less.
• the optimum degree of density of the agglomerates results in high mechanical stability (higher degree of hardness, lower friability), and, despite of this, the release of the pharmaceutically active agent, i.e. of the ⁇ -lactam antibiotic, from the tablet is considerably quicker.
• a mixture of a ⁇ -lactam antibiotic such as amoxicillin trihydrate with a second pharmaceutically active agent, e.g. potassium clavulanate may easily be produced by mixing agglomerates of a ⁇ -lactam antibiotic, e.g. of amoxicillin trihydrate, which are sufficiently free-flowing and compressible, such as agglomerates obtainable by the process of the present invention, with a second pharmaceutically active agent, which may be generally insufficiently free-flowing and incompressible, such as, e.g. potassium clavulanate having for example a grain size of ca. 5 ⁇ m to 100 ⁇ m which may be a normal grain size in pharmaceutical powders, obtained during production.
• a second pharmaceutically active agent which may be generally insufficiently free-flowing and incompressible, such as, e.g. potassium clavulanate having for example a grain size of ca. 5 ⁇ m to 100 ⁇ m which may be a normal grain size in pharmaceutical powders, obtained during production
• the weight ratio of agglomerats of a ⁇ -lactam antibiotic, such as amoxycillin trihydrate and potassium clavulanate in the directly compressable mixture may be in the range of 12:1 to 1:1; e.g. 7:1 to 1:1; such as 4:1 to 1:1; for example 2:1 to 1:1.
• ⁇ -lactam antibiotic agglomerates with a second pharmaceutically active agent, e.g. potassium clavulanate, e.g. in form of a powder, may be effected, e.g. in a forced-flow or free-fall mixer.
• Agglomerates of a ⁇ -lactam antibiotic according to the present invention e.g. agglomerates of amoxycillin trihydrate may function as a carrier for for the second pharmaceuticalle active agent, e.g. potassium clavulanate, e.g. in form of a powder.
• auxiliaries which are preferably pharmaceutically acceptable, for example auxiliaries conventional in tablet formation processes, such as for example lubricants, e.g. magnesium stearate; mold-separating agents, e.g. talcum; binding or filling agents, e.g. polyvinyl pyrrolidone, micro-crystalline cellulose (Avicel), modified starch (Starch 1500 J); disintegrating agents, e.g.
• crosslinked carboxymethyl cellulose Ac—Di—Sol
• crosslinked carboxymethyl starch Principal Part 1
• PVPP crosslinked polyvinyl pyrrolidone
• Auxiliaries, optionally pre-dried, may be mixed into the mixture, for example before, during or after mixing of the ⁇ -lactam antibiotic agglomerates with potassium clavulanate powder.
• the water activity of a mixture is described in literature and is generally described to be in the range of 0.2 to 0.6 (optimum 0.4). It has been found surprisingly that the compressability of the mixture according to the present invention is excellent even with substantially low water activity of the mixture, namely ⁇ 0.2, which is a great advantage owing to the moisture sensitivity of e.g. potassium clavulanate.
• the water activity at 25° C. of a amoxycillin trihydrate/potassium clavulanate mixture according to the present invention may be ⁇ 0.1, preferably ⁇ 0.05.
• Mixtures of agglomerates of a ⁇ -lactam antibiotic such as amoxicillin trihydrate with a second pharmaceutically active agent, e.g. potassium clavulanate, include particular preferred ranges in respect with average grain size and distribution of grain size, namely:
• ⁇ 100 ⁇ m 1% to 50%, preferably 10% to 50% 100 ⁇ m to 500 m: 20% to 90%, preferably 30% to 70% 500 ⁇ m to 1000 ⁇ m: 20% to 70%, preferably 10% to 50% >1000 ⁇ m: max. 15%, preferably max. 10% >2000 ⁇ m: max. 0.1%, preferably max. 0.1%.
• the bulk density of the mixture may, for example, be in the range of about 0.3 g/ml to about 0.8 g/ml, e.g. 0.3 g/ml to 0.8 g/ml; such as about 0.4 g/ml to about 0.6 g/ml; e.g. 0.4 g/ml to 0.6 g/ml.
• the angle of respose of the mixture which is a measure for flowability may be, e.g. ⁇ 40°, preferably ⁇ 35°.
• the present invention provides a mixture of
• agglomerates of an active ⁇ -lactam e.g. amoxycillin trihydrate, for example having an average grain size of 100 ⁇ m to 800 ⁇ m, for example 200 ⁇ m to 600 ⁇ m;
• a second active ingredient e.g. a potassium salt of clavulanic acid, e.g. in form of a powder
• the mixture having, for example, the following distribution of grain size:
• ⁇ 100 ⁇ m 1% to 50%, preferably 10% to 50%, 100-500 ⁇ m: 20% to 90%, preferably 30% to 70%, 500-1000 ⁇ m: 20% to 70%, preferably 10% to 50%, >1000 ⁇ m: max, 15%, preferably max. 10%, >2000 ⁇ m: max. 0.1%, preferably max. 0.1%;
• Mixtures of agglomerates of a ⁇ -lactam antibiotic, for example amoxycillin trihydrate and a second pharmaceutically active agent, e.g. potassium clavulanate in form of a powder according to the present invention, containing optionally auxiliaries, may be directly compressed into tablets with high uniformity of the content of active ingredients and high uniformity of tablet weight, satisfactory mechanical stability and rapid release of active ingredient. Since no moisture is necessary in the entire production process of the tablets, potassium clavulanate is not degraded due to moisture effects which in addition ensures high stability of potassium clavulanate in the finished pharmaceutical preparation.
• the present invention provides the use of auxiliary-free ⁇ -lactam antibiotic agglomerates in the production of a mixture of a ⁇ -lactam antibiotic; and a second pharmaceutically active agent, with or without auxiliaries, having for example an average grain size of 100 ⁇ m to 800 ⁇ m; and in a further aspect
• Auxiliary-free agglomerates of ⁇ -lactam antibiotics especially of phenoxymethylpenicillin potassium, amoxicillin trihydrate and cephalexin monohydrate, which is suitable for direct tablet formation, characterised in that the agglomerates have an average volume-based grain size of 200-1000 ⁇ m, preferably 400-600 ⁇ m, with the following distribution of grain size:
• a mixture suitable for direct tablet formation which contains amoxycillin trihydrate and the potassium salt of clavulanic acid as the essential components, characterized in that amoxycillin trihydrate is present in the form of an agglomerate and the mixture has an average grain size of 100-800 ⁇ m, preferably 200-600 ⁇ m, with the following distribution of grain size:
• Tablets produced by compression of a mixture of agglomerates of a ⁇ -lactam antibiotic, such as e.g. amoxicillin trihydrate with a second pharmaceutically active agent, e.g. potassium clavulanate and optionally with auxiliaries, may also be film-coated with film suspensions, dispersions (aqueous or organic solvents) in coating apparatus (drum, fluidized bed), for example as conventional.
• a second pharmaceutically active agent e.g. potassium clavulanate and optionally with auxiliaries
• Tablets e.g. for oral administration comprising compressed agglomerates of a ⁇ -lactam antibiotic, such as e.g. penicillin V potassium, amoxicillin trihydrate, cephalexin monohydrate optionally in mixture with pharmaceutically acceptable auxiliaries are new and form also part of the present invention.
• a ⁇ -lactam antibiotic such as e.g. penicillin V potassium, amoxicillin trihydrate, cephalexin monohydrate optionally in mixture with pharmaceutically acceptable auxiliaries are new and form also part of the present invention.
• the present invention provides a tablet for e.g. oral administration comprising compressed agglomerates of a ⁇ -lactam antibiotic optionally in mixture with pharmaceutically acceptable auxiliaries.
• Tablets e.g. for oral administration, comprising compressed agglomerates of a ⁇ -lactam antibiotic, such as e.g. amoxicillin trihydrate in mixture with a second pharmaceutically active agent, e.g. potassium clavulanate and optionally with pharmaceutically acceptable auxiliaries are new and form also part of the present invention.
• a ⁇ -lactam antibiotic such as e.g. amoxicillin trihydrate
• a second pharmaceutically active agent e.g. potassium clavulanate and optionally with pharmaceutically acceptable auxiliaries
• the present invention provides a tablet, e.g. for oral administration comprising compressed agglomerates of a ⁇ -lactam antibiotic, such as e.g. amoxicillin trihydrate in mixture with a second pharmaceutically active agent, e.g. potassium clavulanate and with or without pharmaceutically acceptable auxiliaries.
• a ⁇ -lactam antibiotic such as e.g. amoxicillin trihydrate
• a second pharmaceutically active agent e.g. potassium clavulanate and with or without pharmaceutically acceptable auxiliaries.
• Isopropanol-moist penicillin V potassium (10% to 20% isopropanol based on moist mass) is agglomerated in a double-screwed extruder (process length 4 D) at 100 kg/h at a maximum torque pick-up of the extrusion screws of 25% to 30%.
• the screws are configured with conveyer elements, and right- and left-handed kneading blocks.
• Acetone-moist amoxicillin trihydrate (10% to 15% acetone based on moist mass) is agglomerated in a double-screwed extruder (process length 3 D) at 150 kg/h at a maximum torque pick-up of the extrusion screws of 25% to 35%.
• the screws are configured with conveyer elements and right- and left-handed kneading blocks.
• Dry cephalexin monohydrate in form of a powder is agglomerated in a double-screwed extruder (process length 4 D) with 50% aqueous ethanol (5% to 15% based on moist mass) at 200 kg/h at a maximum torque pick-up of the extrusion screws of 12% to 18%.
• the screws are configured with conveyer elements and right-handed kneading blocks.
• the tablet ingredients are as follows:
• Penicillin V potassium agglomerated 150.0 kg according to example 1
• auxiliaries are sieved through a 1.0 mm sieve and subsequently mixed for ca. 10 minutes at 20 ram in a freefall mixer (200 liters, Rhonerad) with penicillin V potassium agglomerated according to example 1.
• This mixture is compressed on a rotating press (KILLIAN LX 18) at a rate of 100,000 tablets per hour.
• the tablets disintegrate in water at 37° C. within 6 minutes.
• the tablet ingredients are as follows:
• Amoxicillin trihydrate, agglomerated 172.2 kg according to example 3 Polyvinyl pyrrolidone 3.75 kg Sodium carboxymethyl starch 6.0 kg Cellulose (micro-crystalline), pH 10.2 16.2 kg Magnesium stearate 1.5 kg
• auxiliaries are sieved through a 1.0 mm sieve and subsequently mixed for ca. 10 minutes at 20 rpm in a freefall mixer (300 liters, Rhonerad) with amoxicillin trihydrate agglomerated as in example 3.
• This mixture is compressed on a rotating press (KILLIAN LX 18) at a rate of 85,000 tablets per hour.
• Hardness of the tablets (determined as in example 5): between 130 N and 160 N
• Friability (determined as in example 5): 0.7% (400 revolutions).
• the tablets disintegrate in water at 37° C. within 3 minutes, and, after 20 minutes, 100% of the amoxicillin trihydrate in the tablet have dissolved.
• Amoxycillin trihydrate was agglomerated according to examples 1 to 4.
• composition (% w/w) Agglomerated amoxycillin trihydrate, 77 (+/ ⁇ 10) (calculated as water-free in form of the free acid) Clavulanic acid in form of the potassium salt, 33 (+/ ⁇ 10) (calculated as the free acid)
• Amoxicillin trihydrate agglomerates and potassium clavulanate are mixed for 10 minutes at 20 rpm in a dry atmosphere in a free-fall mixer (Rhoenrad, 10 liter milling drum); the average grain size of the mixture being 320 ⁇ m.
• the mixture is free-flowing.
• Amoxycillin trihydrate was agglomerated according to examples 1 to 4.
• composition (% w/w) Agglomerated amoxycillin trihydrate, 80 (+/ ⁇ 10) (calculated as water-free in form of the free acid) Clavulanic acid in form of the potassium salt, 20 (+/ ⁇ 10) (calculated as the free acid)
• Amoxicillin trihydrate agglomerates and potassium clavulanate are mixed for 3 minutes at 90 rpm in a dry atmosphere in a forced-flow mixer (Stephan UHC 15 liters); the average grain size of the mixture being 340 ⁇ m.
• the mixture is free-flowing.
• Amoxycillin trihydrate was agglomerated according to examples 1 to 4.
• composition (% w/w) Agglomerated amoxycillin trihydrate, 87.5 (+/ ⁇ 10) (calculated as water-free in form of the free acid) Clavulanic acid in form of the potassium salt, 12.5 (+/ ⁇ 10) (calculated as the free acid)
• Amoxicillin trihydrate agglomerates and potassium clavulanate are mixed for 10 minutes at 20 rpm in a dry atmosphere in a free fall mixer (Rhonerad, 10 liters milling drum); the average grain size of the mixture being 450 ⁇ m.
• the mixture is free-flowing.
• composition Agglomerated amoxycillin trihydrate, (% w/w of total mixture weight) (calculated as water-free in form 77 (+/ ⁇ 10) of the free acid) Clavulanic acid in form of the (% w/w of total mixture weight) potassium salt, (calculated as the 33 (+/ ⁇ 10) free acid)
• Crosscarmelose sodium (AcDiSol ®) 0.20 kg Cellulose micro-crystalline 0.50 kg (AVICEL, pH 102)
• auxiliaries are sieved through a 1.0 mm sieve and subsequently mixed under dry atmosphere for 10 minutes at 20 rpm in a freefall mixer (Rhonerad, 10 liters milling drum) with agglomerates of amoxicillin trihydrate and potassium clavulanate as obtained according to example 7.
• This mixture is compressed on a rotating press (PHARMA 1) at a rate of 50,000 tablets per hour.
• Hardness of the tablets (determined as in example 5): between 110 N and 142 N
• Friability (determined as in example 5): 0.7% (400 revolutions).
• composition Agglomerated amoxycillin trihydrate, (% w/w of total mixture weight) (calculated as water-free in form 87.5 (+/ ⁇ 10) of the free acid) Clavulanic acid in form of the (% w/w of total mixture weight) potassium salt, (calculated as the 12.5 (+/ ⁇ 10) free acid)
• auxiliaries are sieved through a 1.0 mm sieve under dry atmosphere and subsequently mixed under dry atmosphere for 10 minutes at 20 rpm in a freefall mixer (Rhonerad, 15 liters milling drum) with agglomerates of amoxicillin trihydrate and potassium clavulanate as obtained according to example 9.
• This mixture is pressed on a rotating tablet press (KILIAN Eifel RUH 3) at a rate of 80,000 tablets per hour.
• Hardness of the tablets (determined as in example 5): between 149 N and 178 N
• Friability (determined as in example 5): 1.1% (400 revolutions).
• the tablets disintegrate in water at 37° C. within 9.05 minutes, and after 30 minutes, more than 90% of the amoxicillin trihydrate and more than 90% of the potassium clavulanate in the tablet have dissolved (Paddel model, water 37° C., 75 rpm).
• Amoxycillin content per tablet (average of 20 tablets): 96 to 102% of theory

Landscapes

• Health & Medical Sciences (AREA)
• Engineering & Computer Science (AREA)
• Life Sciences & Earth Sciences (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Chemical & Material Sciences (AREA)
• Epidemiology (AREA)
• Communicable Diseases (AREA)
• Oncology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Organic Chemistry (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicinal Preparation (AREA)
• Cephalosporin Compounds (AREA)
• Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Applications Claiming Priority (5)

Publications (1)

Family

ID=25592858

Family Applications (1)

Country Status (21)

Cited By (18)

Families Citing this family (17)

Citations (30)

Family Cites Families (3)

• 1997
  • 1997-03-11 TW TW086102973A patent/TWI225402B/zh not_active IP Right Cessation
  • 1997-03-13 PL PL32840097A patent/PL187761B1/pl unknown
  • 1997-03-13 NZ NZ331178A patent/NZ331178A/en not_active IP Right Cessation
  • 1997-03-13 AU AU21560/97A patent/AU715682B2/en not_active Expired
  • 1997-03-13 TR TR1998/01824T patent/TR199801824T2/xx unknown
  • 1997-03-13 EP EP02020921A patent/EP1283034A3/en not_active Withdrawn
  • 1997-03-13 CA CA002245094A patent/CA2245094C/en not_active Expired - Lifetime
  • 1997-03-13 IL IL12549297A patent/IL125492A0/xx not_active IP Right Cessation
  • 1997-03-13 RU RU98118685/14A patent/RU2195265C2/ru active
  • 1997-03-13 CZ CZ0291698A patent/CZ298815B6/cs not_active IP Right Cessation
  • 1997-03-13 US US09/142,183 patent/US6440462B1/en not_active Expired - Lifetime
  • 1997-03-13 SK SK1244-98A patent/SK286749B6/sk not_active IP Right Cessation
  • 1997-03-13 KR KR10-1998-0706492A patent/KR100468204B1/ko not_active IP Right Cessation
  • 1997-03-13 JP JP53229397A patent/JP3822246B2/ja not_active Expired - Lifetime
  • 1997-03-13 ID IDP970815A patent/ID16237A/id unknown
  • 1997-03-13 WO PCT/EP1997/001269 patent/WO1997033564A1/en active IP Right Grant
  • 1997-03-13 CN CNB97192936XA patent/CN1160058C/zh not_active Expired - Lifetime
  • 1997-03-13 EP EP97914235A patent/EP0896526A1/en not_active Withdrawn
  • 1997-03-13 HU HU9900983A patent/HUP9900983A3/hu unknown
  • 1997-03-13 BR BR9708316A patent/BR9708316A/pt not_active IP Right Cessation
  • 1997-03-13 ES ES02020921T patent/ES2193899T1/es active Pending
• 1998
  • 1998-08-25 NO NO19983904A patent/NO326821B1/no not_active IP Right Cessation

Patent Citations (40)

Non-Patent Citations (19)

Also Published As

Similar Documents

Legal Events